Lucid Capital Markets initiates Adlai Nortye stock with buy rating

Lucid Capital Markets initiated Adlai Nortye (NASDAQ: ANL) at Buy with a $49 price target versus a $15.01 share price, implying roughly 226% upside. The thesis centers on AN9025, a pan-RAS(ON) inhibitor, with a key Phase 1 safety, PK and preliminary-efficacy update due in 1H 2027; Lucid estimates $2.46 billion in combined risk-adjusted global peak sales across major indications. ANL shares have already risen 957% year to date, while InvestingPro flags potential overvaluation and other analyst targets range from $20 to $32.

Analysis

ANL’s valuation is being pulled forward to a 2027 clinical readout, leaving little near-term fundamental mechanism for a sustained re-rating once coverage-initiation flows fade. The key underwriting issue is not whether pan-RAS inhibition has activity, but whether ANL can demonstrate a therapeutic-window advantage sufficient to support combination regimens; preclinical differentiation has a low historical translation rate in oncology. With the shares already reflecting a large pipeline premium, any dose-limiting toxicity, weak pharmacokinetic durability, or financing need could drive disproportionate multiple compression over the next 3-12 months.

The more investable expression of pan-RAS validation remains Revolution Medicines (RVMD), whose clinical dataset and balance-sheet profile reduce single-asset and ADR-specific risk relative to ANL. ANL may retain momentum in the immediate term because low-float clinical biotech rallies can detach from probability-weighted value, making outright short exposure hazardous absent confirmed borrow and liquidity. The contrarian view is that a $49 target conflates a long-dated, risk-adjusted commercial framework with a tradable 12-month value: the relevant catalyst is still too distant to justify paying for full combination-use optionality today.

Falsification for the cautious view would be independently reported human data showing clean, durable target exposure at clinically relevant doses, early objective responses across multiple RAS-mutant tumor types, and a funded runway through the pivotal-development decision. Conversely, a secondary offering, discontinuation of either dosing schedule, or evidence that efficacy requires exposure near tolerability limits would likely reset the equity sharply before the planned comprehensive update.

Key Decisions for Investors

• Do not initiate a core long ANL at current levels; treat it as an event-driven watchlist name until human PK, safety, and response data establish a differentiated therapeutic window. Reassess only after a material clinical update or a financing disclosure clarifies dilution risk.
• For a 1-3 month relative-value trade, consider long RVMD / short ANL only if ANL borrow is available and position sizing can tolerate a 30-50% short squeeze. The thesis is that RVMD offers more credible clinical pan-RAS exposure while ANL carries a richer probability-of-success assumption; cover the short if ANL reports durable confirmed responses or favorable exposure-toxicity data.
• If ANL options have adequate open interest, prefer defined-risk put spreads dated beyond the next financing or clinical-update window rather than an outright short. The trade requires confirmation of option liquidity and implied volatility; avoid paying premium if implied volatility already exceeds the expected post-event move.
• Set alerts for cash-runway disclosures, ATM/registered-share capacity, and any update on dose-limiting toxicities. A capital raise at a meaningful discount or safety signal is the nearer-term downside catalyst; absence of either is not, by itself, evidence that the clinical thesis is working.